ACP3 Antibody Therapeutics

About Philochem

Philochem is a discovery-focused biotech subsidiary of the Philogen group, leveraging its leadership in DNA-encoded chemical libraries and phage display to create novel targeted anti-cancer therapies. The company has demonstrated significant validation through a major licensing deal with RayzeBio/Bristol Myers Squibb for its prostate cancer radiopharmaceutical program, OncoACP3, valued at up to $1.35 billion plus royalties. With a strategy centered on ligand-based pharmacodelivery to spare healthy tissues, Philochem advances a pipeline of small molecule therapeutics, antibodies, and radiopharmaceuticals from discovery into clinical development.

Therapeutic Areas